Laurus Labs Ltd. reported profit attributable to equity holders of ₹441.48 crore for the quarter ended Sept. 30, 2026, up from ₹194.97 crore a year earlier, as revenue and operating margins advanced.
Revenue from operations increased 33% to ₹2,206.37 crore from ₹1,653.47 crore. EBITDA rose 78% to ₹762 crore from ₹429 crore, and the EBITDA margin widened to 34.5% from 26.0%, an increase of 8.5 percentage points.
CDMO revenue reached ₹904 crore, up 75% year over year. Small-molecule CDMO contributed ₹875 crore, an 86% increase. Affordable Medicines revenue grew 15% to ₹1,302 crore, while Bio revenue declined 38% to ₹29 crore. Laurus Labs attributed the Bio decrease to campaign phasing.
The consolidated filing listed other income of ₹13.01 crore, down from ₹26.96 crore in the year-earlier quarter. Total tax expense was ₹155.08 crore, compared with ₹75.98 crore. The filing separately reported profit after tax of ₹436.74 crore, versus ₹193.75 crore.
Executive Director and Chief Financial Officer V V Ravi Kumar said growth in commercial supplies helped the company use its capacity more efficiently and support EBITDA margins. Laurus Labs also reported gross margin of 63.0%, up from 59.9%, and credited favorable business mix for the improvement.
In the first half of FY27, capital expenditure amounted to 20% of revenue as Laurus Labs invested in manufacturing expansion and niche capabilities. Laurus Labs declared an interim dividend of ₹1 per share.
The company said its LB-4 fermentation unit, designed for capacity above 400 kiloliters, was progressing as planned. Commissioning is expected by Q3 FY27.
